Inflammatory Bowel Disease News

The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release.

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.

Initiation of biological therapy within the first year of Crohn’s disease diagnosis was associated with a higher rate of transmural healing, as well as decreased risk for bowel damage progression, surgery and therapy escalation.

Long-term filgotinib induced and maintained symptomatic remission and improved health-related quality of life in ulcerative colitis, with no new safety signals reported, according to interim analysis of the SELECTION extension study.

Multidisciplinary care is key when managing patients with pregnancy-related gastrointestinal and liver diseases, with a “paramount goal” of keeping both the patient and the fetus safe, according to an AGA clinical practice update.

Although Skyrizi was noninferior to Stelara in clinical remission at week 24, it was superior in endoscopic remission at week 48 in patients with moderate to severe Crohn’s disease, according to data from the SEQUENCE trial.

Although evidence suggests the risk for cardiovascular events with small-molecule drugs is low in patients with inflammatory bowel disease, experts advise screening for risk factors and stratification before initiation of therapy.

Vedolizumab not only induced endoscopic improvements in patients with chronic pouchitis, but also appeared to improve clinical outcomes at week 34, especially in those who achieved mucosal healing at week 14, research showed.

Skyrizi significantly improved clinical remission rates as both induction and maintenance therapy vs. placebo in patients with moderately to severely active ulcerative colitis, according to data from the phase 3 INSPIRE and COMMAND trials.